RETA Projected Dividend Yield
Cl A/Reata Pharmaceuticals Inc ( NASDAQ : RETA )Reata Pharmaceuticals is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing therapies. Co. focuses on therapeutics for the treatment of diseases with few or no approved therapies. Co.'s main programs are in rare forms of chronic kidney disease (CKD) and a rare neurological disease. Co.'s primary product candidates include bardoxolone methyl (bardoxolone) in patients with CKD caused by Alport syndrome and omaveloxolone in patients with a neurological disorder called Friedreich's ataxia. Both bardoxolone and omaveloxolone activate the transcription factor Nrf2 to normalize mitochondrial function, restore redox balance, and resolve inflammation. 20 YEAR PERFORMANCE RESULTS |
RETA Dividend History Detail RETA Dividend News RETA Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |